Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J C Stoof

Showing results (91-100 of 120) with videos related to

Pageof 12
Sort By:
Journal of Neurology, Neurosurgery, and Psychiatry|February 18, 2003
[(123)I]beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's diseaseA Winogrodzka, P Bergmans, J Booij, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|November 1, 1994
The dopamine D1 agonist SKF 81297 and the dopamine D2 agonist LY 171555 act synergistically to stimulate motor behavior of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian rhesus monkeysR J Vermeulen, B Drukarch, M C Sahadat, et al.
European Journal of Pharmacology|September 15, 1994
Dopamine D1 receptor agonists display a different intrinsic activity in rat, monkey and human astrocytesR J Vermeulen, C A Jongenelen, C H Langeveld, et al.
Journal of Neurology|September 19, 2000
Preclinical (premotor) Parkinson's diseaseE C Wolters, C Francot, P Bergmans, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 24, 2001
Loss of olfaction in de novo and treated Parkinson's disease: possible implications for early diagnosisG Tissingh, H W Berendse, P Bergmans, et al.
Endocrinology|March 1, 1982
D-2 dopamine receptor-mediated inhibition of adenylate cyclase activity in the intermediate lobe of the rat pituitary gland requires guanosine 5'-triphosphateT E Cote, C W Grewe, K Tsuruta, et al.
Neuroscience|January 1, 1987
D-2 dopamine-receptors regulate the release of [3H]dopamine in rat cortical regions showing dopamine immunoreactive fibersJ F Plantjé, H W Steinbusch, J Schipper, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 1, 1988
Biochemical profile of risperidone, a new antipsychoticJ E Leysen, W Gommeren, A Eens, et al.
Journal of Neurology|February 11, 1998
Drug-naive patients with Parkinson's disease in Hoehn and Yahr stages I and II show a bilateral decrease in striatal dopamine transporters as revealed by [123I]beta-CIT SPECTG Tissingh, P Bergmans, J Booij, et al.
Experimental Brain Research|January 1, 1995
Repeated administration of a selective dopamine D2 receptor agonist to 6-OHDA-lesioned rats does not affect the survival and outgrowth of intrastriatal fetal mesencephalic graftsF L Van Muiswinkel, J G Bol, J M Ruijter, et al.
Pageof 12

Showing results (91-100 of 120) with videos related to

Sort By:
Pageof 12
Journal of Neurology, Neurosurgery, and Psychiatry|February 18, 2003
[(123)I]beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's diseaseA Winogrodzka, P Bergmans, J Booij, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|November 1, 1994
The dopamine D1 agonist SKF 81297 and the dopamine D2 agonist LY 171555 act synergistically to stimulate motor behavior of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian rhesus monkeysR J Vermeulen, B Drukarch, M C Sahadat, et al.
European Journal of Pharmacology|September 15, 1994
Dopamine D1 receptor agonists display a different intrinsic activity in rat, monkey and human astrocytesR J Vermeulen, C A Jongenelen, C H Langeveld, et al.
Journal of Neurology|September 19, 2000
Preclinical (premotor) Parkinson's diseaseE C Wolters, C Francot, P Bergmans, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 24, 2001
Loss of olfaction in de novo and treated Parkinson's disease: possible implications for early diagnosisG Tissingh, H W Berendse, P Bergmans, et al.
Endocrinology|March 1, 1982
D-2 dopamine receptor-mediated inhibition of adenylate cyclase activity in the intermediate lobe of the rat pituitary gland requires guanosine 5'-triphosphateT E Cote, C W Grewe, K Tsuruta, et al.
Neuroscience|January 1, 1987
D-2 dopamine-receptors regulate the release of [3H]dopamine in rat cortical regions showing dopamine immunoreactive fibersJ F Plantjé, H W Steinbusch, J Schipper, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 1, 1988
Biochemical profile of risperidone, a new antipsychoticJ E Leysen, W Gommeren, A Eens, et al.
Journal of Neurology|February 11, 1998
Drug-naive patients with Parkinson's disease in Hoehn and Yahr stages I and II show a bilateral decrease in striatal dopamine transporters as revealed by [123I]beta-CIT SPECTG Tissingh, P Bergmans, J Booij, et al.
Experimental Brain Research|January 1, 1995
Repeated administration of a selective dopamine D2 receptor agonist to 6-OHDA-lesioned rats does not affect the survival and outgrowth of intrastriatal fetal mesencephalic graftsF L Van Muiswinkel, J G Bol, J M Ruijter, et al.
Pageof 12